Downloads and Tools

•  Article PDF
  1.08 MB PDF document

Supplemental Material

•  Supplemental File
  423.43 KB PDF document

This is an open access article.
Print this page Email this page

Recipient's Email:

---

Article Citation

RIS
MARC (XML)
FULL CITATION (TXT)

---

Share on Facebook

Authors: Thoraia Shinawi, Victoria K. Hill, Antonis Dagklis, Panagiotis Baliakas, Kostas Stamatopoulos, Angleo Agathanggelou, Tanja Stankovic, Eamonn R. Maher, Paolo Ghia and Farida Latif

Thoraia Shinawi

University of Birmingham; College of Medical and Dental Sciences; School of Clinical and Experimental Medicine; Medical and Molecular Genetics; Edgbaston, Birmingham UK

Victoria K. Hill

University of Birmingham; College of Medical and Dental Sciences; School of Clinical and Experimental Medicine; Medical and Molecular Genetics; Edgbaston, Birmingham UK

Antonis Dagklis

Laboratory of B Cell Neoplasia and Lymphoma Unit; Division of Molecular Oncology and Department of Onco-Hematology; Università Vita-Salute San Raffaele and Istituto Scientifico San Raffaele; Milano, Italy

Panagiotis Baliakas

Hematology Department and HCT Unit; G. Papanicolaou Hospital; Thessaloniki, Greece

Kostas Stamatopoulos

Hematology Department and HCT Unit; G. Papanicolaou Hospital; Thessaloniki, Greece

Angleo Agathanggelou

University of Birmingham; CRUK Institute for Cancer Studies; Birmingham, UK

Tanja Stankovic

University of Birmingham; CRUK Institute for Cancer Studies; Birmingham, UK

Eamonn R. Maher

University of Birmingham; College of Medical and Dental Sciences; School of Clinical and Experimental Medicine; Medical and Molecular Genetics; Edgbaston, Birmingham UK

Paolo Ghia

Laboratory of B Cell Neoplasia and Lymphoma Unit; Division of Molecular Oncology and Department of Onco-Hematology; Università Vita-Salute San Raffaele and Istituto Scientifico San Raffaele; Milano, Italy

Farida Latif

Corresponding author: f.latif@bham.ac.uk
University of Birmingham; College of Medical and Dental Sciences; School of Clinical and Experimental Medicine; Medical and Molecular Genetics; Edgbaston, Birmingham UK

Abstract:
Ras-association domain family (RASSF) members are a family of genes containing an RA domain in either the C-terminus (RASSF1-RASSF6) or in the N-terminus (RASSF7-RASSF10). Members of this gene family are core members of the Salvador/Warts/Hippo (SWH) tumor suppressor network and have been shown to be involved in human tumorigenesis. Among the RASSF genes, RASSF1A is one of the most frequently methylated genes in a wide range of epithelial cancers, and we previously demonstrated that RASSF6 and RASSF10 genes are frequently epigenetically inactivated in acute leukemias, particularly in those of the B cell type. We here determined the methylation profiles of all members of the RASSF gene family as well as two recently identified (KIBRA, CRB3) upstream members of the SWH pathway in the leukemic B cells obtained from a well-characterized cohort of 95 patients with chronic lymphocytic leukemia (CLL). Among the RASSF genes, RASSF10 (50%) was the most frequently methylated gene, followed by RASSF6 (16%). The remaining RASSF genes were either unmethylated or showed a frequency of methylation < 10%. The upstream SWH member KIBRA was also frequently methylated in CLL (35%) in contrast to CRB3. Interestingly, the analysis of clinical-pathological parameters showed that KIBRA methylation was associated with unfavorable biological prognostic parameters, including unmutated IGHV genes (p = 0.007) and high CD38 expression (p < 0.05).

Received: September 30, 2011; Accepted: December 30, 2011

Preview: